The DPP-4* inhibitor linagliptin ably demonstrated cardiovascular (CV) and renal safety in a new analysis of the CARMELINA trial that stratified diabetes patients across age groups and kidney function.
The SGLT2* inhibitor canagliflozin reduced the risk of major cardiovascular (CV) and renal events in patients with type 2 diabetes (T2D) who had not previously experienced a CV event, according to an update on the CREDENCE** trial presented at ADA 2019.
The rate of progression to type 2 diabetes (T2D) among people with prediabetes who had initially lost weight on a low-calorie diet (LCD) was low and comparable between two different diet and weight management programmes, according to the results of the PREVIEW* study presented at the 79th Scientific Sessions of the American Diabetes Association in San Francisco.
Diabetes increases the risk of death, particularly from cardiovascular diseases (CVD), infections, cancer and renal failure, reports a new China study presented at the recently concluded 79th Scientific Sessions of the American Diabetes Association (ADA 2019) held in San Francisco, California.
Children with early-onset type 1 diabetes (T1D) and poor glycaemic control have a slower growth of brain regions associated with sensory processing and cognition compared with nondiabetic controls, according to a longitudinal study of brain growth by the DirecNet*.
Once-weekly injection of dulaglutide 1.5 mg significantly delayed kidney function decline and progression to end-stage kidney disease (ESKD) compared with insulin glargine in patients with type 2 diabetes (T2D) and moderate-to-severe chronic kidney disease (CKD), particularly in those with macroalbuminuria, according to a post hoc analysis of AWARD-7* presented at ADA 2019.
Patients with type 2 diabetes (T2D) and high cardiovascular (CV) risk do not have an elevated risk of major adverse CV events (MACE)* when taking oral semaglutide alongside standard-of-care (SOC) therapy, according to findings of the PIONEER 6** trial presented at ADA 2019.
Dual sodium-glucose linked transporter 1 and 2 inhibition with sotagliflozin confers cardiorenal protective benefits in patients with type 1 diabetes, with the drug inducing blood pressure reductions, albuminuria declines and estimated glomerular filtration rate changes, according to a study presented at the 79th Scientific Sessions of the American Diabetes Association (ADA 2019).
An international panel consisting of 43 experts from around the globe has established evidence-based guidelines for continuous glucose monitoring (CGM), providing “time-in-range” (TIR) targets for people with diabetes who are using CGM, according to an abstract presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) at Moscone Convention Center in San Francisco.
The optimal blood pressure (BP) goal for adults with childhood-onset type 1 diabetes (T1D) to reduce their risk of cardiovascular disease (CVD) may be lower than the current ADA*-recommended threshold of 130/80 mm Hg or 140/90 mm Hg**, according to data presented at ADA 2019.